Checkpoint Therapeutics, Inc. (CKPT)

NASDAQ: CKPT · IEX Real-Time Price · USD
2.050
+0.010 (0.49%)
Mar 28, 2024, 4:30 PM EDT - Market closed
0.49%
Market Cap 73.16M
Revenue (ttm) 103,000
Net Income (ttm) -51.85M
Shares Out 22.83M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 345,753
Open 2.070
Previous Close 2.040
Day's Range 2.020 - 2.100
52-Week Range 1.300 - 3.620
Beta 1.00
Analysts Strong Buy
Price Target 22.60 (+1,002.44%)
Earnings Date Mar 22, 2024

About CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigg... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2017
Employees 23
Stock Exchange NASDAQ
Ticker Symbol CKPT
Full Company Profile

Financial Performance

In 2023, CKPT's revenue was $103,000, a decrease of -46.35% compared to the previous year's $192,000. Losses were -$51.85 million, -17.21% less than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CKPT stock is "Strong Buy." The 12-month stock price forecast is $22.6, which is an increase of 1,002.44% from the latest price.

Price Target
$22.6
(1,002.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial ...

Other symbols: FBIO
6 days ago - GlobeNewsWire

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appoin...

10 days ago - GlobeNewsWire

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has...

2 months ago - GlobeNewsWire

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James ...

2 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Checkpoint Therapeutics, Inc. - CKPT

NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT). Such investors are...

2 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Checkpoint Therapeutics, Inc. - CKPT

NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT). Such investors are advised to ...

3 months ago - PRNewsWire

Checkpoint Therapeutics slides after US FDA declines cancer therapy approval

Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an inspection at a contract manuf...

3 months ago - Reuters

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab FDA did not state any concerns about the clinical data package, safety, or labe...

3 months ago - GlobeNewsWire

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoin...

4 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy of C...

4 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous s...

5 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry i...

6 months ago - GlobeNewsWire

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...

6 months ago - GlobeNewsWire

Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...

7 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024

8 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market

WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has...

8 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favor...

8 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing

Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date ...

9 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has ...

11 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 FDA acce...

11 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it ha...

1 year ago - GlobeNewsWire

Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 FDA acce...

1 year ago - GlobeNewsWire

Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting

1 year ago - GlobeNewsWire

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has...

1 year ago - GlobeNewsWire

Checkpoint Therapeutics to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James ...

1 year ago - GlobeNewsWire